You are here: Industry Insights > Indoco

News List

Indoco launches Brinzolamide Ophthalmic Suspension 1% in US by Teva Pharma expresspharma
March 10, 2021
Indoco Remedies announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US, the first generic version of AZOPT by Teva Pharmaceuticals. The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa.
Indoco launches favipiravir 400 mg tablets expresspharma
September 28, 2020
Fevindo - 400 will be made available at all government approved COVID care centres and selected medical practitioners across the country.
Indoco gets USFDA nod for apixaban tablets expresspharma
September 15, 2020
Apixaban is an anticoagulant, or blood thinner used for patients with health problems caused by a blood clot.
Indoco gets USFDA approval for Olanzapine tablets expresspharma
August 07, 2020
Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder.
Indoco receives US FDA approval for Succinylcholine Chloride Injection USP expresspharma
May 28, 2020
Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Indoco’s CRO – AnaCipher clears US FDA inspection with ZERO 483 expresspharma
August 15, 2019
Indoco Remedies announced that its Clinical Research Organisation, AnaCipher , located at Hyderabad had undergone a walk-in surveillance inspection by the United States Food and Drug Administration (division of New Drug Bioequivalence Evaluation) from 5th
USFDA clears Indoco’s Goa Plant II and III expresspharma
July 30, 2019
Indoco Remedies has announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for their sterile facility (Plant II) and solid dosages facility (Plant III) at Verna, Goa.
Indoco’s Goa Plant I receives Warning Letter from US FDA expresspharma
July 17, 2019
Indoco Remedies has received a Warning Letter from The United States Food and Drug Administration for its Oral dosages Plant, situated at L -14, Verna Industrial Road, Goa, after an inspection which was carried out in January 2019.
Indoco declares Q1FY19 results financialexpress
August 16, 2018
Indoco Remedies posted revenues of INR 212.5 crores during the first quarter of FY 2018-19, as against INR 204.2 crores, for the same quarter last...
Indoco facilities bag US FDA nod financialexpress
May 21, 2018
Indoco Remedies announced the successful completion of US FDA inspection at its API manufacturing facilities at Patalganga and Rabale, Navi Mumbai.

Previous page 1 2 Next page